During a Divestiture, Is "Clone and Go" the Right Way to Go?
Steve Sapletal discusses the "clone and go" approach
Date : November 28, 2014

New business units need to forge their own paths and adopting parent company practices is rarely the best approach.


Though the state of the global economy is gradually improving, one thing has stayed constant: organizations are looking to maximize the value of their business unit portfolio. This is no truer in any industry than Big Pharma, where main players like Johnson & Johnson and Quest Diagnostics are shedding parts of their businesses to drive revenue by dropping low-performing divisions. As this trend quickly becomes an industry norm, life sciences and pharmaceutical firms are faced with the tough decision: how to successfully manage complex divestitures and create a new entity without wreaking havoc on the existing business.

To view the full article as it appeared on Genetic Engineering & Biotechnology News, please click here.

West Monroe Partners Plans to Double Workforce to Help Address IT Skills Gap
View More
Related News
Kyle Sarausky recognized for leadership and mentorship in mergers & acquisitions
Date : July 6, 2017
Private equity and corporate buyers search for quality over economy in software M&A
Date : June 7, 2017
Date : February 7, 2017
New York City-based Director adds more than 20 years of private equity & consulting experience